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p53 in resected oropharyngeal carcinoma
Michaela Plath1,2, Martina A. Broglie1,4, Diana Förbs3, Sandro J. Stoeckli1 and Wolfram Jochum3*
Abstract
Background: Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has an
improved outcome and may allow for treatment de-escalation. High-risk HPV (HR-HPV) infection is associated with
deregulated expression of the cell cycle-associated proteins p16INK4, pRB, cyclin D1 and p53. The objective of this
study was to assess cell cycle proteins as potential surrogate markers for HR-HPV DNA testing to identify OPSCC
with favorable prognosis after resection.
Methods: Tissue microarray cores of 313 surgically treated OPSCC were stained for p16INK4a, pRB, cyclin D1 and p53
using immunohistochemistry. Protein expression was scored as high or low based on the proportion of positive
carcinoma cells. Tumor samples were analysed for HR-HPV DNA with polymerase chain reaction-based testing.
Associations between cell cycle protein expression and HR-HPV DNA status were evaluated by calculating
sensitivity, specificity, predictive values, and diagnostic odds ratios (DOR). Kaplan-Meier and Cox regression analysis
were applied to evaluate associations between cell cycle protein expression and patient outcome.
Results: High expression of p16INK4a, cyclin D1, pRB and p53 in tumor cells were observed in 51.8%, 51.4%, 41.9%
and 33.5% of OPSCC, respectively. HR-HPV DNA positive were 158/313 (50.5%) tumor samples (HPV16: 147, HPV18:
1, HPV33: 5, HPV35: 2, HPV56: 2, and HPV59: 1). P16INK4a showed a higher DOR to predict HR-HPV DNA positivity
than pRB, cyclin D1 and p53. Both the p16INK4a/pRB and the p16INK4a/pRB/cyclin D1/p53 signatures had lower DOR
than p16INK4a alone. Improved 5-year overall and disease-specific survival were associated with HR-HPV DNA
positivity, high p16INK4a, low pRB, low cyclin D1, and low p53 expression. Associations with improved outcome were
also observed for the marker combinations high p16INK4a/positive HR-HPV DNA, high p16INK4a/low pRB and high
p16INK4a/low pRB/low cyclin D1/low p53. In a multivariate analysis adjusted for age, smoking history, pT and pN
category, high p16INK4a expression showed the lowest hazard ratio for death.
Conclusions: High p16INK4a expression is a reliable marker for survival prognostication in surgically treated OPSCC
patients. Protein signatures including the pRB, cyclin D1 and p53 proteins do not further increase the prognostic
performance of p16INK4a as a single marker.
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Background
High-risk human papillomavirus (HR-HPV) infection is a
major cause of oropharyngeal squamous cell carcinoma
(OPSCC) [1]. HPV-related OPSCC has better prognosis,
irrespective of disease stage [2–4]. Treatment options for
patients with early OPSCC include surgical resection with
or without adjuvant radio (chemo)therapy or primary ra-
dio(chemo)therapy. Identification of the prognostic impact
of HPV has lead to the development of risk-adapted sta-
ging systems for HPV-related OPSCC, and to the adapta-
tion of the current American Joint Committee on Cancer
(AJCC)/Union for International Cancer Control (UICC)
TNM staging classification [2–5]. These developments
underscore the increasing clinical significance of HPV sta-
tus in OPSCC und the need for establishing the HPV sta-
tus of OPSCC prior to treatment initiation.
HR-HPV infection of tumor cells is associated with the
expression of the viral E6 and E7 oncoproteins [6]. Both
proteins are essential to induce and maintain cellular trans-
formation, due to their interference with cell cycle control,
apoptosis, and genomic stability. In addition to other target
proteins, E6 promotes the degradation of the p53 protein,
which regulates growth arrest and apoptosis after DNA
damage. E7 increases degradation of the cellular retino-
blastoma protein (pRB), which leads to up-regulation of
p16INK4a and down-regulation of cyclin D1. Disruption of
both the p53 and pRB pathways promotes S-phase entry.
The tumor cell signature of high p16INK4a expression and
low/absent expression of cyclin D1, pRB and p53 correlates
with HR-HPV infection [7]. Furthermore, deregulated ex-
pression of these cell cycle regulators has been linked to
outcome prediction in OPSCC. High p16INK4a expression
of tumor cells was associated with favorable prognosis and
high cyclin D1 and p53 expression of tumor cells was
linked to poor outcome [8–19]. However, evaluation of the
prognostic significance of deregulated cell cycle regulator
expression in OPSCC has been restricted by usage of differ-
ent immunohistochemical staining methods, scoring sys-
tems, and thresholds, and most importantly heterogeneity
of patient cohorts with respect to disease stage and treat-
ment modalities.
The objectives of our study were to validate p16INK4a as
a prognostic marker in a large cohort of surgically treated
OPSCC, and to directly compare the performance of
p16INK4a with pRB, cyclin D1 and p53 to predict patient
outcome. The second objective was to evaluate the cell
cycle proteins p16INK4a, pRB, cyclin D1 and p53 as surro-
gate markers for HR-HPV DNA positivity.
Methods
Patient population
The cohort of this study represents a subgroup of a pre-
vious reported cohort [20]. Demographic and clinical
data were collected by chart review. The patients were
categorized into two groups based on treatment: Group 1
was treated with resection alone (n = 104; 33.2%), group 2
with resection and adjuvant radio(chemo)therapy (n = 209;
66.8%). Pathological staging was performed using the
7th edition of the AJCC/UICC TNM classification
system (2010).
Histological analysis
One representative formalin-fixed paraffin-embedded tissue
block of each OPSCC resection specimen was retrieved.
Hematoxylin and eosin (H&E) staining of sections was per-
formed using standard techniques. Stained sections under-
went histological review to confirm the presence of
carcinoma.
Tissue microarray
Formalin-fixed paraffin-embedded OPSCC tissue samples
were used to construct tissue microarrays (TMA). Three
cores (diameter 2 mm) with tumor tissue were punched
out of each donor block and transferred to the recipient
block. Tissue cores from tonsils of non-tumor patients were
included as controls. H&E stained TMA sections were
microscopically evaluated for the presence of tumor cells.
Immunohistochemistry
Three-μm thick tissue microarray sections were deparaffi-
nized followed by antigen retrieval (EDTA pH 9.0, 95 °C,
30 min). Stainings were performed on a Leica BOND MAX
instrument (Leica) using the Bond Polymer Refine detection
kit (Leica) and the following primary antibodies: p16INK4a
(clone E6H4, dilution 1:10, 30 min; MTM Laboratories,
Heidelberg, Germany), pRB (clone 13A10, dilution 1:100,
15 min; Novocastra), cyclin D1 (clone SP4, dilution 1:50,
30 min; ThermoScientific), and p53 (clone DO-7, dilution
1:150, 30 min; Dako). Marker expression was scored as high
or low based on the proportion of positive carcinoma cells
(high p16INKa: more than 70% of tumor cells; high pRB, cyc-
lin D1, or p53: more than 25% of tumor cell nuclei) [19, 21].
HPV DNA analysis
Tumor cells were located and marked on H&E stained tis-
sue sections obtained from paraffin blocks of primary
OPSCC. Selective dissection of tumor cells was performed
from three to five 4 μm thick serial tissue sections of the
same paraffin block and genomic DNA was prepared. HPV
DNA was detected by polymerase chain reaction
(PCR)-based amplification using the L1C1/L1C2 consensus
primer set as previously described [22]. PCR products were
purified using the QIAGEN PCR purification Kit (QIA-
GEN) and underwent direct sequencing for HPV typing.
Negative and positive controls were included in each HPV
PCR run. Beta-globin PCR was performed for samples with
negative HPV PCR to test for effective DNA extraction and
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DNA integrity. Only samples with amplifiable DNA were
scored as negative for HPV.
Statistical analysis
All analyses were performed with the SPSS Statistics 22
software (IBM Corporation, Armonk NY). Demographic
and clinicopathological patient characteristics were investi-
gated with descriptive statistics. Associations between cell
cycle protein expression and HR-HPV DNA status were
analyzed using the chi-square test. Specificity, sensitivity,
positive predictive values (PPV), negative predictive values
(NPV), and diagnostic odds ratios (DOR) were calculated
to evaluate cell cycle proteins and expression signatures as
potential surrogate markers for HR-HPV DNA positivity.
Overall survival (OS) was defined as time from the date of
cancer diagnosis to the date of death, disease-specific sur-
vival (DSS) as the time from the date of cancer diagnosis to
the date of death from OPSCC. Five-year OS and DSS rates
were calculated using the Kaplan-Meier method. Univariate
Cox proportional hazard models were used to explore asso-
ciations between patient characteristics, biomarker results,
OS and DSS. Hazard ratios (HR) with 95% confidence in-
tervals were calculated. The Cox proportional hazard
model was used for multivariate analysis. P values of < 0.05
were considered statistically significant.
Results
Patient cohort
Three hundred thirteen patients with surgically treated
and histologically confirmed OPSCC were included in the
analysis. The clinicopathological characteristics of the pa-
tient cohort are shown in Table 1.
Cell cycle protein expression
In non-neoplastic tonsils, scattered epithelial cells showed
weak to moderate p16INK4a reactivity. pRB was strongly
expressed in the nuclei of basal and parabasal epithelial
Table 1 Clinicopathological characteristics of the study population
Characteristic Entire cohort
(n = 313)
Resection only group
(n = 104)
Resection with adjuvant therapy group
(n = 209)
Mean age (range) 68 (35–101) 68 (47–101) 68 (35–100)
Gender
Male 230 (73.5%) 71 (68.3%) 159 (76.1%)
Female 83 (26.5%) 33 (31.7%) 50 (23.9%)
Smoking history
> 10 pack-years 221 (70.6%) 78 (75.0%) 143 (68.4%)
< 10 pack-years 92 (29.4%) 26 (25.0%) 66 (31.6%)
Alcohol intake
< 3 U/d 164 (52.4%) 52 (50.0%) 112 (53.6%)
> 3 U/d 113 (36.1%) 40 (38.5%) 73 (34.9%)
Missing data 36 (11.5%) 12 (11.5%) 24 (11.5%)
Primary site
Tonsil 217 (69.3%) 68 (65.4%) 149 (71.3%)
Base of tongue 58(18.5%) 16 (15.4%) 42 (20.1%)
Posterior wall / soft palate 38 (12.2%) 20 (19.2%) 18 (8.6%)
Tumor stage
T1/T2 263 (84.0%) 96 (92.3%) 167 (79.9%)
T3/T4 50 (16.0%) 8 (7.7%) 42 (20.1%)
Nodal stage
N0 92 (29.4%) 58 (55.8%) 34 (16.3%)
N+ 221 (70.6%) 46 (44.2%) 175 (83.7%)
HR-HPV DNA
Positive 158 (50.5%) 42 (40.4%) 116 (55.5%)
Negative 155 (49.5%) 62 (59.6%) 93 (44.5%)
5-year overall survival rate 76.1% 69.8% 79.1%
5-year disease-specific survival rate 85.2% 83.1% 86.2%
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cells, which also showed weak to moderate nuclear cyclin
D1 and p53 staining (data not shown).
We next evaluated cell cycle protein expression in tissue
cores of 313 OPSCC (Fig. 1, Table 2). Strong p16INK4a stain-
ing in more than 70% of carcinoma cells was observed in
52.1% of OPSCC. pRB and cyclin D1 reactivity was low (<
25% of tumor cells) or absent in 48.6% and 57.8% of
OPSCC, respectively. Nuclear p53 positivity stronger than
in tonsillar epithelial cells was observed in 33.5% of tumors.
A high p16INK4a/low pRB signature of tumor cells was
present in 45.4% of OPSCC. Thirty-eight percent of the
OPSCC displayed a high p16INK4a/low pRB/low cyclin D1/
low p53 signature.
Association of cell cycle protein expression with HR-HPV
DNA
HPV DNA testing was conclusive in all 313 OPSCC. 158
(50.5%) tumors were HR-HPV DNA positive (HPV16:
147, HPV18: 1, HPV33: 5, HPV35: 2, HPV56: 2, and
HPV59: 1). HR-HPV DNA positive OPSCC were positive
for p16INK4a, pRB, cyclin D1and p53 in 91.8%, 17.1%,
15.8%, and 14.6%, respectively (Table 2). There was a
strong association between HR-HPV DNA positivity and
high p16INK4a expression. In addition, HR-HPV DNA
positivity was also correlated with low pRB, low cyclin D1
and low p53 expression. There was also a strong associ-
ation between HR-HPV DNA positivity and both the
2-marker signature high p16INK4a/low pRB and the
4-marker signature high p16INK4a/low pRB/low cyclin D1/
low p53. High p16INK4a expression alone displayed the
highest sensitivity value for HR-HPV DNA positivity. In
contrast, the 4-marker signature showed the highest speci-
ficity value. To directly compare the performance of indi-
vidual cell cycle proteins and the two marker signatures to
detect HR-HPV DNA positive OPSCC, diagnostic odds
ratios (DOR) were calculated. The value of a DOR ranges
from 0 to infinity, with higher values indicating better dis-
criminatory test performance. The largest DOR value was
observed for high p16INK4a expression alone (Table 2).
Association of cell cycle protein expression with survival
after resection
The mean follow-up period of the cohort was 119 months
(range 6–172 months). The 5-year OS and DSS rates were
76.1% and 85.2%, respectively. Kaplan-Meier analysis
demonstrated that both improved OS and DSS were asso-
ciated with HR-HPV DNA positivity, and high p16INK4a,
low pRB, low cyclin D1 and low p53 expression of tumor
cells (Fig. 2, Table 3).
Univariate Cox regression analysis revealed reduced over-
all risks of death for OPSCC with HR-HPV DNA positivity
and high p16INK4a expression (Table 3). In contrast, hazard
ratios (HR) were increased for OPSCC with high pRB, high
cyclin D1, or high p53 expression. The combined
parameters high p16INK4a/positive HR-HPV DNA, high
p16INK4a/low pRB, and high p16INK4a/low pRB/low cyclin
D1/low p53 were also associated with reduced overall risks
of death. Comparable results were obtained for the
risk of disease-specific death, which was evaluated as
an additional outcome parameter (Table 3). We also
used Cox proportional hazard models adjusted for age,
smoking history, pT stage and pN stage to evaluate and
compare the prognostic impact of the various parameters.
Parameters retained prognostic significance in multivari-
ate analyses except high cyclin D1 and p53 expression
(Table 4).
We also performed subgroup analyses for OPSCC pa-
tients with or without adjuvant treatment after resection.
For both subgroups, similar associations between the
various parameters and patient outcome were observed
as for the entire cohort (data not shown).
Discussion
Among patients with OPSCC, HR-HPV infection of tumor
cells is associated with favorable prognosis, and therefore
may identify patients who benefit from treatment
de-escalation. Various methods are available for HR-HPV
testing. HR-HPV E6/E7 messenger RNA (mRNA) expres-
sion demonstrated by reverse transcriptase-PCR or RNA in
situ hybridization (ISH) is considered the most specific
marker for biologically relevant HPV infection because it
identifies transcriptionally active HPV infection and indi-
cates the translation of the viral E6 and E7 oncoproteins
[23]. In addition, HR-HPV DNA can be detected by poly-
merase chain reaction (PCR)-based assays or ISH tech-
niques with HPV type-specific probes [24]. HPV E6 and E7
oncoproteins induce p16INK4a protein overexpression and
suppress the expression of the cell cycle proteins pRB, cyc-
lin D1 and p53 in infected cells [6]. Recent studies have
shown that the combined detection of HR-HPV DNA (by
PCR or ISH) and p16INK4a protein overexpression identifies
transcriptionally active HR-HPV infection with specificity
and sensitivity comparable to those of E6/E7 mRNA ex-
pression [14, 23, 25]. However, the availability of molecular
detection methods for HR-HPV DNA or HR-HPV E6/E7
mRNA is limited. In contrast, immunohistochemistry for
protein expression analysis is broadly available and there-
fore may be used as a fast and inexpensive methodology to
assess tumor cells for HR-HPV-related protein deregulation
in the clinical setting. The 8th edition TNM classification
for head and neck cancer distinguishes between OPSCC
with and without HPV association, and recommends
p16INK4a immunostaining for the identification of tumors
with positive HPV status, based on the conclusion that
p16INK4a is a reliable surrogate marker for oncologically
relevant HPV infection [26]. In HR-HPV infected tumor
cells, increased p16INK4a expression is a direct consequence
of pRB inactivation by the HPV oncoprotein E7, which
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Fig. 1 Expression of cell cycle-associated proteins in oropharyngeal squamous cell carcinoma. Histological findings (a, b) and expression of the
p16INK4a (c, d), pRB (e, f), cyclin D1 (g, h) and p53 (i, j) proteins in representative HR-HPV positive (b, d, f, h, j) and HR-HPV negative OPSCC (a, c,
e, g, i). Original magnification, 400×
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induces degradation through the ubiquitin-proteasome
pathway [27]. However, using p16INK4a expression
alone as a biomarker for positive HR-HPV status
may have limitations due to HR-HPV-independent
mechanisms of up-regulation.
In our study, we aimed to evaluate pRB, cyclin D1 and
p53 as alternative marker for HR-HPV DNA positivity, and
to address the question whether protein signatures includ-
ing pRB, cyclin D1 and p53 may increase the diagnostic
performance of p16INK4a alone. In accordance with other
studies, we observed that HPV-associated OPSCC are char-
acterized by strong p16INK4a expression and low or absent
expression of pRB, cyclin D1, und p53 [7, 18, 19]. Among
the four cell cycle-associated proteins, high p16INK4a stain-
ing showed the strongest association with HR-HPV DNA
positivity when evaluated as a single marker (sensitivity
92%, specificity 88%). The associations between low/
absent expression of pRB, cyclin D1, or p53 alone and
HR-HPV DNA positivity were significantly lower. In com-
parison to high p16INK4a expression alone, we observed
higher specificity values for the 2-marker signature high
p16INK4a/low pRB and the 4-marker signature p16INK4a/
pRB/cyclin D1/p53, but reduced sensitivity values. Using
the diagnostic odds ratio as a performance parameter, high
p16INK4a expression alone was the best immunohisto-
chemical marker for HR-HPV DNA positivity. Our find-
ings confirm p16INK4a as a reliable surrogate marker for
HR-HPV infection in OPSCC. They also indicate that sig-
natures including the pRB, cyclin D1 and p53 proteins do
not significantly increase the diagnostic performance of
p16INK4a as a single marker.
Treatment options for patients with early OPSCC include
surgical resection with or without adjuvant radio(chemo)-
therapy, or primary radio(chemo)therapy. In addition to its
Table 2 Association between cell cycle protein expression and HR-HPV DNA status
Cell cycle
protein
Entire
cohort
HR-HPV DNA
negative
HR-HPV DNA positive Pearson Chi-
square
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
DOR
(n = 313) (n = 155) All
(n = 158)
HPV16
(n = 147)
Non-HPV16
(n = 11)
p value
p16INK4a < 0.001 91.8 89.0 89.5 91.4 90.3
Low 151
(48.2%)
138 (89.0%) 13 (8.2%) 13 (8.8%) 0 (0%)
High 162
(51.8%)
17 (11.0%) 145
(91.8%)
134
(91.2%)
11
(100.0%)
pRB < 0.001 82.9 86.5 86.2 83.2 31.1
Low 152
(48.6%)
21 (13.5%) 131
(82.9%)
121
(82.3%)
10 (91.0%)
High 161
(51.4%)
134 (86.5%) 27
(17.1%)
26
(17.7%)
1 (9.0%)
Cyclin D1 < 0.001 84.2 68.4 73.1 80.9 11.5
Low 181
(57.8%)
48 (31%) 133
(84.2%)
124
(84.3%)
9 (81.8%)
High 132
(42.2%)
107 (69%) 25
(15.8%)
23
(15.7%)
2 (18.2%)
p53 < 0.001 85.4 53.9 64.9 78.1 6.8
Low 208
(66.5%)
73 (47.1%) 135
(85.4%)
127
(86.4%)
8 (72.7%)
High 105
(33.5%)
82 (52.9%) 23
(14.6%)
20
(13.6%)
3 (27.3%)
p16INK4a/pRB < 0.001 82.9 92.9 92.3 84.2 63.8
High/low 142
(45.4%)
11 (7.1%) 131
(82.9%)
121
(82.3%)
10 (90.9%)
Other 171
(54.6%)
144 (92.9%) 27
(17.1%)
26
(17.7%)
1 (9.1%)
p16 INK4a/pRB/ cyclin D1/p53 < 0.001 68.4 93.5 91.5 74.4 30.9
High/low/
low/low
118
(37.7%)
10 (6.5%) 108
(68.4%)
102
(69.4%)
6 (54.6%)
Other 195
(62.3%)
145 (93.5%) 50
(31.6%)
45
(30.6%)
5 (45.4%)
PPV positive predictive value, NPV negative predictive value (%); and DOR diagnostic odds ratio. Non-HPV16 group included tumors positive for HPV18, HPV33,
HPV35, HPV56, or HPV59
Plath et al. Journal of Otolaryngology - Head and Neck Surgery  (2018) 47:53 Page 6 of 9
role in tumorigenesis, HR-HPV infection identifies OPSCC
patients with improved survival who may benefit from
treatment de-escalation [10, 20, 28]. Previous studies have
shown that HR-HPV DNA detection alone, the combined
detection of HR-HPV DNA and p16INK4a protein, p16INK4a-
protein expression alone, or HR-HPV E6/E7mRNA ex-
pression identify OPSCC patients with favorable prognosis
[9–12, 14, 15]. Furthermore, poor prognosis has been
linked to high cyclin D1 and p53 expression of tumor cells
[8, 13, 16–18]. In the majority of theses studies, associ-
ation analysis of the various markers with survival was
confounded by treatment heterogeneity of cohorts and/or
limited patient numbers. Only few previous studies
have investigated cohorts of surgically treated
OPSCC [18, 29–31]. In the current study, we analyzed the
prognostic significance of cell cycle protein expression in
a large cohort of surgically treated OPSCC patients from
the same geographic region [20]. Univariate analysis re-
vealed that improved outcome after resection (both 5-year
OS and DSS) were associated with high p16INK4a, low
pRB, low cyclin D1, and low p53 expression. Furthermore,
HR-HPV DNA positivity and the combined parameters
high p16INK4a/positive HR-HPV DNA, high p16INK4a/low
pRB, and high p16INK4a/low pRB/low cyclin D1/low p53
were also associated with reduced risks of death. Parame-
ters retained prognostic significance in multivariate ana-
lyses except high cyclin D1 and p53 expression. Our
results confirm the findings of previous studies and valid-
ate them specifically for surgically treated OPSCC patients
[8–19, 23]. They indicate that high p16INK4a expres-
sion provides comparable prognostic information as
HR-HPV DNA positivity in surgically treated OPSCC
A B
C D
E F
Fig. 2 Overall survival after resection in patients with oropharyngeal squamous cell carcinoma. Kaplan-Meier analyses revealed associations between
improved survival and HR-HPV DNA positivity (a), high p16INK4a (b), low pRB (c), high p16INK4a/low pRB signature (d), low cyclin D1 (e), and low p53 (f)
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patients and may therefore serve as a reliable surrogate
marker for improved prognosis, if HR-HPV DNA testing
is not available.
Limitations of our study include that cell cycle protein
expression analyses were performed on TMA cores that
may not be representative of the whole tumor. However,
various studies have shown excellent concordance between
TMA spots and whole tissue sections in immunohisto-
chemical analyses of multiple tumor types. Furthermore,
each tumor was represented by three tissue cores in our
study to increase concordance. Two individuals blinded for
HR-HPV DNA results and clinical outcome information
scored all immunohistochemical stainings. However, digital
image analysis may have increased standardization of
scoring. We used HR-HPV DNA positivity as the gold
standard to evaluate cell cycle proteins as potential surro-
gate markers for HR-HPV infection. However, HR-HPV
E6/E7 mRNA detection is considered the best marker for
biologically relevant HR-HPV infection. Further studies are
necessary to directly compare the performance of p16INK4a
expression and HR-HPV E6/E7 mRNA detection in surgi-
cally treated OPSCC.
Conclusion
In conclusion, our results show that immunohistochemi-
cal demonstration of high p16INK4a expression in tumor
cells is a reliable tool for survival prognostication in sur-
gically treated OPSCC patients. Protein signatures in-
cluding the pRB, cyclin D1 and p53 proteins do not
further increase the prognostic and diagnostic perform-
ance of p16INK4a as a single marker. Therefore, p16INK4a
may be used to select OPSCC patients with improved
prognosis for treatment de-escalation, especially in the
absence of HR-HPV DNA and HR-HPV E6/E7 mRNA
testing.
Table 4 Multivariate analysis of overall and disease-specific survival for patients with OPSCC patients treated with resection
5-year overall survival 5-year disease-specific survival
Parameter HR (95% CI) p value HR (95% CI) p value
HR-HPV DNA (Positive vs. negative) 0.46 (0.26–0.81) 0.007 0.41 (0.18–0.90) 0.027
p16INK4a (High vs. low) 0.23 (0.16–0.57) < 0.001 0.22 (0.09–0.52) 0.001
pRB (High vs. low) 2.54 (1.46–4.41) 0.001 3.20 (1.46–6.99) 0.004
Cyclin D1 (High vs. low) 1.59 (0–2.55) 0.053 1.55 (0.82–2.94) 0.18
p53 (High vs. low) 1.79 (1.12–2.86) 0.015 1.52 (0.80–2.87) 0.20
High p16INK4a/HR-HPV DNA positive vs. others 0.30 (0.16–0.57) < 0.001 0.26 (0.10–0.64) 0.004
High p16INK4a/low pRB vs. others 0.32 (0.18–0.45) < 0.001 0.25 (0.11–0.60) 0.002
High p16INK4a/low pRB/low cyclin D1/low p53 vs. others 0.36 (0.19–0.38) 0.001 0.25 (0.09–0.65) 0.005
Abbreviations: HR hazard ratio for death, CI confidence interval; P < 0.05 was considered statistically significant
Table 3 Univariate analysis of overall and disease-specific survival for patients with OPSCC patients treated with resection
N = 313 5-year overall survival 5-year disease-specific survival
Parameter % P value HR (95% CI) P value % P value HR (95% CI) P value
Age (> 65 y vs. < 65 y) 75.6/77.1 0.83 1.05 (0.66–1.68) 0.83 85.3/84.9 0.88 1.05 (0.56–1.99) 0.88
Smoking history (> 10 py vs. < 10 py) 70.9/88.5 0.002 2.53 (1.37–4.69) 0.003 80.8/95.8 0.003 4.19 (1.49–11.77) 0.006
Tumor stage (T3/T4 vs. T1/T2) 64.7/78.5 0.15 1.48 (0.87–2.55) 0.15 74.6/87.4 0.023 2.15 (1.09–4.21) 0.03
Nodal stage (N+ vs. N0) 73.5/82.0 0.31 1.3 (0.78–2.16) 0.31 83.2/90.2 0.14 1.77 (0.82–3.84) 0.15
HR-HPV DNA (Positive vs. negative) 85.9/66.8 < 0.001 0.39 (0.24–0.64) < 0.001 91.6/78.9 < 0.001 0.30 (0.15–0.62) 0.001
p16INK4a (High vs. low) 89.6/64.5 < 0.001 0.29 (0.15–0.44) < 0.001 93.2/80.9 < 0.001 0.21 (0.1–0.46) < 0.001
pRB (High vs. low) 67.6/85.5 < 0.001 2.68 (1.63–4.43) < 0.001 78.8/92.2 < 0.001 3.56 (1.70–7.47) 0.001
Cyclin D1 (High vs. low) 67.6/82.0 0.009 1,79 (1.15–2.80) 0.01 81.9/87.7 0.068 1.76 (0.95–3.25) 0.07
p53 (High vs. low) 66.2/81.2 0.002 1.99 (1.27–3.10) 0.002 79.1/88.2 0.053 1.82 (0.98–3.36) 0.06
High p16INK4a/HR-HPV DNA positive vs. others 85.9/66.8 < 0.001 0.39 (0.24–0.64) < 0.001 91.6/78.9 < 0.001 0.30 (0.15–0.62) 0.001
High p16INK4a/low pRB vs. others 87.7/67.0 < 0.001 0.32(0.18–0.54) < 0.001 93.2/78.7 < 0.001 0.23 (0.10–0.52) < 0.001
High p16INK4a/low pRB/low cyclin D1/low p53 vs. others 88.3/69.9 < 0.001 0.33 (0.18–0.59) < 0.001 94.1/80.0 < 0.001 0.21 (0.08–0.55) 0.001
Abbreviations: HR hazard ratio for death, CI confidence interval; py pack-year. Log-rank test. p < 0.05 was considered statistically significant
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NPV: Negative predictive value; OPSCC: Oropharyngeal squamous cells
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